|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000036682 |
|
最近更新日期: Date of Last Refreshed on: |
2020-09-19 20:30:52 |
|
注册时间: Date of Registration: |
2020-08-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
周晓琳医师:请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件。 脑梗死和神经变性病患者唾液无创诊断生物标志物研究 |
|
Public title: |
Non-invasive salivary biomarkers for diagnosis of stroke and neurodegeneration diseases |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脑梗死和神经变性病患者唾液无创诊断生物标志物研究 |
|
Scientific title: |
Non-invasive salivary biomarkers for diagnosis of stroke and neurodegeneration diseases |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周晓琳 |
研究负责人: |
周晓琳 |
|
Applicant: |
Xiaolin Zhou |
Study leader: |
Xiaolin Zhou |
|
申请注册联系人电话: Applicant telephone: |
+86 18602185973 |
研究负责人电话: Study leader's telephone: |
+86 18602185973 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhou_xiaolin@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhou_xiaolin@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市虹口区海宁路100号 |
研究负责人通讯地址: |
上海市虹口区海宁路100号 |
|
Applicant address: |
100 Haining Road, Hongkou District, Shanghai, China |
Study leader's address: |
100 Haining Road, Hongkou District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市第一人民医院 |
||
|
Applicant's institution: |
Shanghai First People's Hospital |
||
|
研究负责人所在单位: |
上海市第一人民医院 |
||
|
Affiliation of the Leader: |
Shanghai First People's Hospital |
||
|
是否获伦理委员会批准: |
否/No |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
上海市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai First People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市虹口区海宁路100号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
100 Haining Road, Hongkou District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市自然科学基金面上项目、国家自然科学基金青年项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Natural Science Foundation; China NSFC Youth Research Grant |
||||||||||||||||||||||
|
Target disease: |
stroke and neurodegeneration diseases |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
析因分组(即根据危险因素或暴露因素分组) |
||||||||||||||||||||||
|
Study design: |
Factorial |
||||||||||||||||||||||
|
研究目的: |
本研究在现有肠道菌群与神经系统疾病的关系基础上开展口腔菌群与急性缺血性脑卒中(脑梗死)及神经变性疾病(阿尔茨海默病和原发性帕金森病)的临床相关性研究,筛查相关疾病的口腔菌群特异性生物标记物,为后续开发疾病诊断、预测、治疗预后判断的标记物试剂盒做前期临床研究,以及寻找后续进一步的疾病病理生理研究和治疗的靶点。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the existing relationship between intestinal flora and nervous system diseases, the clinical correlation between oral flora and acute ischemic stroke (cerebral infarction) and neurodegenerative diseases (Alzheimer's disease and primary Parkinson's disease) was carried out to screen the specific biomarkers of oral flora of related diseases, so as to develop disease diagnosis, prediction and prognosis judgment Objective: to do preliminary clinical research and find the target of further pathophysiological research and treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 依据TOAST分型符合大动脉粥样硬化性脑梗死患者200例; |
||||||||||||||||||||||
|
Inclusion criteria |
1. According to toast classification, there were 200 patients with large atherosclerotic cerebral infarction; |
||||||||||||||||||||||
|
排除标准: |
1个月内口服过抗生物、佩戴假牙、缺少8颗以上牙齿。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Those who took oral antibiotics, wore dentures and lacked more than 8 teeth within one month. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-10-01 00:00:00至 To 1990-01-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-10-01 00:00:00 至 To 1990-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
经过明确诊断的相关疾病患者随即入组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
After a clear diagnosis of related diseases, patients were enrolled. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文发表 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Paper publication |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF; Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |